Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects

NCT ID: NCT07163182

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-15
• Study Completion Date: 2026-08-11

Brief Summary

A clinical trial to investigate the safety and tolerability of single and multiple intranasal (through the nose) dosing with the study drug CHF6467 in 68 healthy adult subjects.

The study will investigate also how CHF6467 moves and behaves in the blood and in the fluid around the brain and spinal cord (cerebrospinal fluid) and if the drug CHF6467 causes an immune response by looking for specific molecules, called antibodies that may form against it.

The study will be divided into two parts - Part 1 (testing single ascending doses of the study drug, SAD, lasting 4 days) and Part 2 (testing repeated or multiple ascending doses of the study drug, MAD, lasting 11 days).

Each part of the study consists of a screening period, when eligible healthy volunteers will be selected, a treatment period, during which the study drug administration will take place and a follow-up period.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Test Treatment

Intranasal (IN) CHF6467

Group Type: ACTIVE_COMPARATOR

CHF6467 Part 1 (SAD)

Intervention Type: BIOLOGICAL

Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts

CHF6467 Part 2 (MAD)

Intervention Type: BIOLOGICAL

Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts

Reference Treatment

Intranasal (IN) placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2

Interventions

CHF6467 Part 1 (SAD)

Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts

Intervention Type: BIOLOGICAL

CHF6467 Part 2 (MAD)

Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts

Intervention Type: BIOLOGICAL

Placebo

Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subject's written informed consent obtained prior to any study-related procedures;

2. Willingness and ability to understand the risks involved and to understand and comply with the study procedures;

3. Healthy male and female subjects, aged 18-55 years inclusive at screening;

4. Weight ≥ 50 kg and <85 kg and Body Mass Index (BMI) between 18.0 and 30.0 kg/m² inclusive at screening and on Day -1;

5. Non-smoker or ex-smoker who smoked less than 5 pack years (Pack years = the number of cigarette packs per day times the number of years) and stopped smoking at least 1 year prior to screening;

6. Good physical condition and mental status determined by the Investigator, based on the subject's medical history and general clinical examination at screening and Day -1;

7. Vital signs within normal limits at screening and at Day-1: 60 mmHg ≤ diastolic blood pressure (DBP) ≤ 89 mmHg, 90 mmHg ≤ systolic blood pressure (SBP) ≤ 139 mmHg (three measures performed after at least 5 minutes of resting; the mean value must be within the defined range). Axillary body temperature of 35.5-37.0º Celsius inclusive;

8. Bedside 12-lead electrocardiogram (ECG) considered as normal (45 bpm ≤ heart rate [HR] ≤ 100 bpm, 120 ms ≤ PR interval [PR] ≤ 210 ms, QRS interval [QRS] ≤ 120 ms, QT interval [QT] corrected using Fridericia's formula [QTcF] ≤ 450 ms for males and ≤ 470 ms for females) at screening visit and Day -1; the mean value of three measurements must be within the range.

9. Males fulfilling one of the following criteria:

1. Males with pregnant or non-pregnant women of childbearing potential (WOCBP) partners: they must be willing to use male condom from the signature of the informed consent and until the follow-up visit or

2. Non-fertile male subjects (contraception is not required in this case) or

3. Males with partner not of childbearing potential (contraception is not required in this case);

10. Female subjects fulfilling one of the following criteria:

1. Women of non-childbearing potential (WOCBP) defined as physiologically incapable of becoming pregnant (i.e., post-menopausal or permanently sterile). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per Investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone (FSH) levels (according to local laboratory ranges);

2. WOCBP fulfilling one of the following criteria:

i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method preferably with low user dependency from the signature of the informed consent and until the follow-up visit; or ii. WOCBP with non-fertile male partners (contraception is not required in this case).

Exclusion Criteria

1. The subject has taken non-permitted concomitant medications in the predefined period prior to screening or prior to randomisation or is expected to take non-permitted concomitant medications during the study;

2. Participation to investigational study: subjects who have received any investigational drug within the 30 days (60 days for biologics) or a more appropriate time as determined by the Investigator (e.g. approximately 5 half-lives of the investigational drug whatever is longer);

3. Significant nasal congestion or signs of nasal damage, bleeding, excoriation or ulceration at physical examination at screening or Day -1;

4. History of frequent nosebleeds;

5. Any ongoing acute (e.g. non-allergic rhinitis) or chronic (e.g. chronic rhinosinusitis or chronic purulent postnasal drip) condition of the nasal cavity, or clinically significant physical finding (e.g. nasal polyps, nasal structural abnormalities, nasal trauma, severe nasal septal deviation) which, in the opinion of the Investigator, can interfere with the administration or absorption of the study medication. Subjects with recent upper respiratory tract infections will be allowed in the study only if their nasal symptoms have been completely resolved for more than 2 weeks prior to screening;

6. Clinically significant abnormal 24-hour Holter at screening;

7. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic or psychiatric disorder that may interfere with successful completion of this protocol, any known malignancies, or any condition that in Investigator's opinion may pose the subject at risk from participating in the study;

8. Any clinically relevant abnormal laboratory value at screening or Day -1suggesting an undiagnosed condition that requires further clinical investigation or may impact the safety of the subject or the evaluation of the study results according to the Investigator's judgement; Note: In case of abnormal laboratory values that could indicate a temporary condition, the test can be repeated once before randomisation;

9. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed at Day -1.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chiesi Farmaceutici S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maya Dabcheva, MD

Role: PRINCIPAL_INVESTIGATOR

MC Comac Medical Ltd.

Locations

Bulgaria MC Comac Medical Ltd.

Sofia, , Bulgaria

Site Status: RECRUITING

Countries

Bulgaria

Central Contacts

Chiesi Clinical Trial Info

Role: CONTACT

clinicaltrials_info@chiesi.com

+39 0521 2791

Facility Contacts

Maya Dabcheva, MD

Role: primary

Other Identifiers

2025-521455-23-00

Identifier Type: CTIS

Identifier Source: secondary_id

CLI-06467AC1-02

Identifier Type: -

Identifier Source: org_study_id